Last reviewed · How we verify

Sibutramine-Metformin — Competitive Intelligence Brief

Sibutramine-Metformin (Sibutramine-Metformin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antiobesity and antidiabetic agent. Area: Endocrinology / Obesity / Diabetes.

phase 3 Combination antiobesity and antidiabetic agent Norepinephrine transporter (NET), serotonin transporter (SERT); AMP-activated protein kinase (AMPK) Endocrinology / Obesity / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Sibutramine-Metformin (Sibutramine-Metformin) — Laboratorios Silanes S.A. de C.V.. Sibutramine-Metformin is a combination drug that suppresses appetite through norepinephrine reuptake inhibition while improving insulin sensitivity and glucose metabolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sibutramine-Metformin TARGET Sibutramine-Metformin Laboratorios Silanes S.A. de C.V. phase 3 Combination antiobesity and antidiabetic agent Norepinephrine transporter (NET), serotonin transporter (SERT); AMP-activated protein kinase (AMPK)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antiobesity and antidiabetic agent class)

  1. Laboratorios Silanes S.A. de C.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sibutramine-Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/sibutramine-metformin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: